HLN.L (LSE) is a cross-listing of HLN (NYSE). Showing primary listing data.
HLN
Haleon plc
1W: -5.5%
1M: -12.1%
3M: -2.3%
YTD: -2.6%
1Y: -2.2%
3Y: +28.0%
$9.74
+0.04 (+0.41%)
After Hours: $9.77 (+0.03, +0.31%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$43.5B
52W Range8.71-11.42
Volume7,932,508
Avg Volume8,188,508
Beta0.25
Dividend$0.18
Analyst Ratings
Company Info
CEOBrian James McNamara
Employees24,561
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2022-07-25
Websitehaleon.com
Building 5
Weybridge KT13 0NY
GB
Weybridge KT13 0NY
GB
44 1932 822000
About Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Latest News
Quantbot Technologies LP Sells 88,712 Shares of Haleon PLC Sponsored ADR $HLN
Citigroup Inc. Buys 64,298 Shares of Haleon PLC Sponsored ADR $HLN
Haleon PLC Sponsored ADR (HLN) Moves to Buy: Rationale Behind the Upgrade
Haleon's weaker sales make mid-term targets 'not look credible'
Haleon plc (HLN) Q4 2025 Earnings Call Prepared Remarks Transcript
Recent Insider Trades
No insider trades found